Literature DB >> 10571594

Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era?

P J Bus1, I D Nagtegaal, H W Verspaget, C B Lamers, H Geldof, J H Van Krieken, G Griffioen.   

Abstract

BACKGROUND: It is an accepted fact that non-steroidal anti-inflammatory drugs (NSAIDs) are potent inhibitors of colorectal carcinogenesis. However, the major disadvantages of NSAIDs are gastrointestinal and renal toxicity. We conducted a prospective pilot study on the effects of the safe salicylic acid derivative, mesalazine, on apoptosis and proliferation of tumour cells and on normal tissue in colorectal cancer patients.
METHODS: Patients with colorectal cancer were asked to take mesalazine enemas for 14 days. Biopsies from malignant and normal tissue were taken prior to and after this treatment. Apoptosis was scored on haematoxylin/eosin-stained tissue sections, and cell proliferation was assessed by the proliferation marker Ki-67.
RESULTS: Ten out of 14 patients completed the study. The apoptotic score increased significantly in the tumour samples (pre-treatment 14.6 +/- 1.3 vs. post-treatment 19.4 +/- 0.8; P < 0.03). The apoptotic index in the normal mucosa was unchanged (pre-treatment 3.1 +/- 0.4 vs. post-treatment 2.9 +/- 0.3; N.S.). The cell proliferation in malignant tissue, according to the Ki-67 score, was hardly affected by mesalazine (pre-treatment 522 +/- 38 vs. post-treatment 493 +/- 39; N.S.). There was no effect on the Ki-67 index of normal mucosa (pre-treatment 24.2 +/- 2.0 vs. post-treatment 28.3 +/- 2.0; N.S.).
CONCLUSIONS: This pilot study conducted in patients with colorectal cancer clearly shows that mesalazine selectively induces apoptosis of tumour cells. On the basis of these findings, which need to be confirmed in larger studies, it may be speculated that 5-ASA could be useful in the chemoprevention of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571594     DOI: 10.1046/j.1365-2036.1999.00652.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  27 in total

Review 1.  Molecular basis of the potential of mesalazine to prevent colorectal cancer.

Authors:  Carmine Stolfi; Roberto Pellegrini; Eleonora Franze; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

Review 2.  5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.

Authors:  T P van Staa; T Card; R F Logan; H G M Leufkens
Journal:  Gut       Date:  2005-06-30       Impact factor: 23.059

3.  Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.

Authors:  Manisha Bajpai; Darren N Seril; James Van Gurp; Xin Geng; Janet Alvarez; Carlos D Minacapelli; Steve Gorin; Koushik K Das; Elizabeth Poplin; Jerry Cheng; Peter S Amenta; Kiron M Das
Journal:  Dig Dis Sci       Date:  2018-11-26       Impact factor: 3.199

Review 4.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 5.  5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.

Authors:  Yang Cheng; Pierre Desreumaux
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

6.  Radiation induces different changes in expression profiles of normal rectal tissue compared with rectal carcinoma.

Authors:  I D Nagtegaal; C G S Gaspar; L T C Peltenburg; C A M Marijnen; E Kapiteijn; C J H van de Velde; R Fodde; J H J M van Krieken
Journal:  Virchows Arch       Date:  2004-12-16       Impact factor: 4.064

7.  Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.

Authors:  Joel H Rubenstein; Akbar K Waljee; Joanne M Jeter; Fernando S Velayos; Uri Ladabaum; Peter D R Higgins
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

8.  5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro.

Authors:  Hai-Ming Fang; Qiao Mei; Jian-Ming Xu; Wei-Juan Ma
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

9.  Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia.

Authors:  Koushik K Das; Manisha Bajpai; Yingxin Kong; Jianying Liu; Xin Geng; Kiron M Das
Journal:  Mol Pharmacol       Date:  2009-04-15       Impact factor: 4.436

10.  Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study.

Authors:  Jonathan P Terdiman; Lorin K Johnson; Young S Kim; Marvin H Sleisenger; James R Gum; Ann Hayes; Vivian K Weinberg; Kenneth R McQuaid
Journal:  Dig Dis Sci       Date:  2009-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.